GlobalData on MSN7 小时
Vicebio secures $100m to advance RSV and hMPV vaccine combo to Phase I
UK-based startup Vicebio has raised $100m to advance its “next-generation vaccines” for respiratory illnesses, including ...
labiotech15 小时
Vicebio and its molecular clamp vaccine raise big to tackle respiratory viruses
Discover Vicebio's molecular clamp technology as it completes a $100 million series B round for its bivalent vaccine against ...
Proteomics reports positive results for PromarkerEso oesophageal cancer test
The PromarkerEso diagnostic blood test is intended for early detection and treatment of EAC, a form of oesophageal cancer.
Medindia16 小时
Vicebio Announces $100 Million Series B Financing and Initiation of Phase 1 Clinical Study ...
Financing led by new investor TCGX, alongside Goldman Sachs Alternatives, Avoro Ventures and venBio Funding will support and accelerate development of next-generation multivalent ...
Proteomics International Laboratories Ltd (ASX:PIQ) Esophageal Cancer Diagnostic Delivers ...
Proteomics International Laboratories Ltd (ASX:PIQ), a pioneer in predictive diagnostics and precision <a target=_blank href= ...